"Our strong first-quarter results demonstrate the continued momentum in our business, driven by growing awareness and customer satisfaction with our G6 CGM technology," said Dexcom CEO Kevin Sayer.And while I think investors should keep an eye on the competition, I believe Dexcom is poised to remain a leader in the CGM business, and the company will continue to outperform the market in the long run.